24 Aug 2021

UCB Announces European Commission Approval of BIMZELX[®]▼ (bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

Read More
20 Aug 2021

Disposals of own shares

Read More
13 Aug 2021

Disposals of own shares

Read More
9 Aug 2021

Transparency notification FMR LLC.

Read More
7 Aug 2021

New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Read More
6 Aug 2021

Disposals of own shares

Read More
2 Aug 2021

Disposals of own shares

Read More
29 Jul 2021

First half 2021 with sustainable performance – delivering on UCB’s strategy and guidance

Read More
23 Jul 2021

Disposals of own shares

Read More
Subscribe to